ChiCTR1900021309 版本V1.6 版本创建时间2019/02/18 11:56:08 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR1900021309 

最近更新日期:

Date of Last Refreshed on:

2019-02-18 11:55:50 

注册时间:

Date of Registration:

2019-02-13 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

目标导向液体治疗联合预防性给予不同剂量去甲肾上腺素对老年脊柱外科患者术后转归的影响

Public title:

The perioperative effect of Goal-directed fluid therapy combined with different dose of norepinephrine in elderly patients undergoing spinal surgery: a randomized controlled trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

目标导向液体治疗联合预防性给予不同剂量去甲肾上腺素对老年脊柱外科患者术后转归的影响

Scientific title:

Perioperative effect of Goal-directed fluid therapy combined with different dose of norepinephrine in elderly patients undergoing spinal surgery: a randomized controlled trial

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

吴凡 

研究负责人:

吴凡 

Applicant:

Wu Fan 

Study leader:

Wu Fan 

申请注册联系人电话:

Applicant telephone:

+86 18686096424

研究负责人电话:

Study leader's
telephone:

+86 18686096424

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

baobaoisshit@163.com

研究负责人电子邮件:

Study leader's E-mail:

baobaoisshit@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国内蒙古呼和浩特市新城区光明路观府小区f栋三单元

研究负责人通讯地址:

中华人民共和国内蒙古呼和浩特市新城区光明路观府小区f栋三单元

Applicant address:

Unit 3, Building F, Guanfu Residential Area, Guangming Road, Xincheng District, Hohhot, Inner Mongolia, China

Study leader's address:

Unit 3, Building F, Guanfu Residential Area, Guangming Road, Xincheng District, Hohhot, Inner Mongolia, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学宣武医院

Applicant's institution:

Xuanwu Hospital Capital Medical University

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY(2018022)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

内蒙古医科大学附属医院伦理委员会

Name of the ethic committee:

Ethics Committee of Inner Megolia Medicai University

伦理委员会批准日期:

Date of approved by ethic committee:

2018-09-19 00:00:00

伦理委员会联系人:

张晓燕

Contact Name of the ethic committee:

Xiao yan Zhang

伦理委员会联系地址:

内蒙古呼和浩特市回民区通道北街1号

Contact Address of the ethic committee:

1 Tongdao Street North, Huimin District, Hohhot, Inner Mongolia

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 0471 3451027

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学宣武医院

Primary sponsor:

Xuanwu Hospital Capital Medical University

研究实施负责(组长)单位地址:

北京市西城区长椿街45号

Primary sponsor's address:

45 Changchun Street, Xicheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中华人民共和国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院

具体地址:

西城区长椿街45号

Institution
hospital:

Xuanwu Hospital Capital Medical University

Address:

45 Changchun Street, Xicheng District

国家:

中华人民共和国

省(直辖市):

内蒙古自治区

市(区县):

呼和浩特市

Country:

China

Province:

Inner Mongolia Autonomous Region

City:

Hohhot

单位(医院):

内蒙古医科大学附属医院

具体地址:

内蒙古呼和浩特市回民区通道北街1号

Institution
hospital:

the Affiliated Hospital of Inner Mongolia Medical University

Address:

1 Tongdao Street North

经费或物资来源:

2015登峰人才计划

Source(s) of funding:

“Deng Feng” Talent Program

研究疾病:

脊柱外科疾病  

Target disease:

Spinal surgery diseases

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

上市后药物 

Study phase:

4

研究设计:

不同剂量对照 

Study design:

Dose comparison 

研究目的:

阐明PPV指导目标导向液体治疗(GDFT)联合合适剂量去甲肾上腺素否实现围术期体液零平衡策略以及显著改善老年脊柱患者的术后转归。  

Objectives of Study:

Objective To clarify whether PPV-guided goal-directed fluid therapy (GDFT) combined with appropriate dose of norepinephrine have following effectszero balance of body fluids during perioperative period and improving postoperative outcomes significantly in elderly patients undergoing spinal surger.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. ASA≤3级;
2. 年龄65-85岁;
3. 性别不限;
4. 全身麻醉下腰椎椎管减压、内固定术。

Inclusion criteria

1. ASA≤III;
2. Aged 65 to 85 years;
3. No limitation for gender;
4. Decompression and internal fixation of lumbar vertebral under general anesthesia.

排除标准:

1. 患者拒绝参加实验;
2. 肾功能障碍者;
3. 肝功能不全者;
4. 甲亢患者;
5. 闭塞性血管炎、血栓病患者;
6. 活动性消化道溃疡患者;
7. 炎症性肠炎、缺血性肠病患者;
8. 充血性心力衰竭患者;
9. 术前心电图检查异常者 (包括窦速、窦缓、房室传导阻滞);10合并心脏瓣膜疾病、肥厚型心肌病或严重肺部疾病的患者。

Exclusion criteria:

1. Inability to comply with the study protocal;
2. Renal dysfunction;
3. Hyperthyreosis;
4. Thromboarteritis obliterans;
5. Peptic ulcer;
6. Hepatic dysfunctio;
7. Ischemic enteritis;
8. Congestive heart failure;
9. Abnormal electrocardiogram;
10. Valvular heart disease, Hypertrophic cardiomyopathy, severe pulmonary disease.

研究实施时间:

Study execute time:

From 2019-03-01 00:00:00 To 2020-01-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-03-01 00:00:00 To 2019-09-01 00:00:00

干预措施:

Interventions:

组别:

N1

样本量:

40

Group:

N1

Sample size:

干预措施:

去甲肾上腺素0.03μg·kg-1·min-1

干预措施代码:

Intervention:

Norepinephrine 0.03μg·kg-1·min-1

Intervention code:

组别:

N2

样本量:

40

Group:

N2

Sample size:

干预措施:

去甲肾上腺素0.06μg·kg-1·min-1

干预措施代码:

Intervention:

Norepinephrine 0.06μg·kg-1·min-1

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中华人民共和国

省(直辖市):

内蒙古自治区 

市(区县):

 

Country:

China

Province:

Inner Mongolia Autonomous Region

City:

单位(医院):

内蒙古医科大学附属医院 

单位级别:

三级甲等综合医院 

Institution
hospital:

the Affiliated Hospital of Inner Mongolia Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后并发症的发生率

指标类型:

主要指标

Outcome:

Incidence of postoperative complications

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清ANP、NT-proBNP,Syndecan-1浓度的变化、肠排气时间、经口摄食摄饮时间、术后住院时间、围术期输血输液总量

指标类型:

次要指标

Outcome:

Changes of serum ANP, NT-proBNP and Syndecan-1 levels

Type:

Secondary indicator

测量时间点:

术前、术后

测量方法:

Measure time point of outcome:

Before and after operation

Measure method:

指标中文名:

肠排气时间

指标类型:

次要指标

Outcome:

Time of intestinal exhaust

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

经口摄食摄饮时间

指标类型:

次要指标

Outcome:

Time of oral intake and drinking

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后住院时间

指标类型:

次要指标

Outcome:

Time of hospitalization after operation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

围术期输血输液总量

指标类型:

次要指标

Outcome:

Total amount of transfusion during perioperative period

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究负责人吴凡采用随机数字表法进行随机

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table method is adopted by study leader wufan

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲

Blinding:

Double Blind

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

https://www.xwhosp.com.cn/

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

https://www.xwhosp.com.cn/

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本次研究采用CRF进行数据采集与管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRF is used to collect and manage data in this research

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-02-13 11:30:14